marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q2
added 08-13-2024
Ocuphire Pharma Balance Sheet 2011-2024 | OCUP
Annual Balance Sheet Ocuphire Pharma
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
- | - | - | -16.4 M | 4.13 M | - | - | - | - | - | - | - | - |
Long Term Debt |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
- | - | - | - | 140 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | 28 M | - | - | - | - | - | - | - | - | - |
Total Current Liabilities |
4.04 M | 2.75 M | 3.86 M | 3.18 M | 2.91 M | - | - | - | - | - | - | - | - |
Total Liabilities |
4.04 M | 2.75 M | 3.86 M | 31.1 M | 9.34 M | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-81.5 M | -71.5 M | -89.4 M | -32.7 M | -8.06 M | - | - | - | - | - | - | - | - |
Total Assets |
53.9 M | 49 M | 26.1 M | 17.7 M | 1.78 M | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
50.5 M | 42.6 M | 24.5 M | 16.4 M | 1.54 M | 8.74 M | 8.9 M | 11.6 M | 10.2 M | 9.83 M | 18.7 M | 13.5 M | 9.86 M |
Book Value |
49.9 M | 46.2 M | 22.2 M | -13.5 M | -7.56 M | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
49.9 M | 46.2 M | 22.2 M | -13.5 M | -7.56 M | 10.6 M | 16.8 M | 17.1 M | 18.8 M | 26.6 M | 12.6 M | 9.53 M | 10.7 M |
All numbers in USD currency
Quarterly Balance Sheet Ocuphire Pharma
| 2024-Q2 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 25.8 K | 63.6 K | 100 K | 63.6 K | 63.6 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
4.2 M | 4.04 M | 3.91 M | 5.76 M | 4.15 M | 2.75 M | 2.69 M | 3.3 M | 3.21 M | 3.86 M | 2.64 M | 2.7 M | 2.31 M | 31.1 M | 31.1 M | 31.1 M | 31.1 M | 9.34 M | 3.01 M | 3.01 M | 3.01 M | 5.48 M | 5.48 M | 5.48 M | 5.48 M | 11.5 M | 11.5 M | 11.5 M | 11.5 M | 3.99 M | 3.99 M | 3.99 M | 3.99 M | 6.03 M | 6.03 M | 6.03 M | 6.03 M | 6.95 M | 6.95 M | 6.95 M | 6.95 M | 6.93 M | 6.93 M | 6.93 M | 6.93 M | 5.39 M | 5.39 M | 5.39 M | 5.39 M | 2.98 M | 2.98 M | 2.98 M | 2.98 M |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | 650 K | 650 K | 600 K | 1.5 M | 1.5 M | 1.5 M | 1.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-96.3 M | -81.5 M | -76.7 M | -82.2 M | -77.3 M | -71.5 M | -105 M | -101 M | -96 M | -89.4 M | -83.1 M | -78.8 M | -71.7 M | -32.7 M | -32.7 M | -32.7 M | -32.7 M | -8.06 M | -163 M | -163 M | -163 M | -155 M | -155 M | -155 M | -155 M | -140 M | -140 M | -140 M | -140 M | -115 M | -115 M | -115 M | -115 M | -106 M | -106 M | -106 M | -106 M | -91.3 M | -91.3 M | -91.3 M | -91.3 M | -72.8 M | -72.8 M | -72.8 M | - | - | - | - | - | - | - | - | - |
Total Assets |
44.8 M | 53.9 M | 54.2 M | 43.5 M | 45.4 M | 49 M | 14.6 M | 17.9 M | 20.5 M | 26.1 M | 23.2 M | 25.3 M | 12.1 M | 17.7 M | 17.7 M | 17.7 M | 17.7 M | 1.78 M | 13 M | 13 M | 13 M | 16 M | 16 M | 16 M | 16 M | 28.3 M | 28.3 M | 28.3 M | 28.3 M | 21 M | 21 M | 21 M | 21 M | 24.8 M | 24.8 M | 24.8 M | 24.8 M | 33.5 M | 33.5 M | 33.5 M | 33.5 M | 19.6 M | 19.6 M | 19.6 M | 19.6 M | 14.9 M | 14.9 M | 14.9 M | 14.9 M | 13.7 M | 13.7 M | 13.7 M | 13.7 M |
Cash and Cash Equivalents |
41.4 M | 50.5 M | 42.4 M | 40 M | 39 M | 42.6 M | 13.9 M | 17 M | 19.2 M | 24.5 M | 22.2 M | 24.2 M | 10.6 M | 16.4 M | 16.4 M | 16.4 M | 16.4 M | 1.54 M | 9.22 M | 9.22 M | 9.22 M | 8.74 M | 4.59 M | 5.09 M | 6.3 M | 8.9 M | 8.9 M | 8.9 M | 8.9 M | 11.6 M | 11.6 M | 11.6 M | 11.6 M | 10.2 M | 10.2 M | 10.2 M | 10.2 M | 9.83 M | 9.83 M | 9.83 M | 9.83 M | 18.7 M | 18.7 M | 18.7 M | 18.7 M | 13.5 M | 13.5 M | 13.5 M | 13.5 M | 9.86 M | 9.86 M | 9.86 M | 9.86 M |
Book Value |
40.6 M | 49.9 M | 50.3 M | 37.7 M | 41.2 M | 46.2 M | 11.9 M | 14.6 M | 17.3 M | 22.2 M | 20.6 M | 22.6 M | 9.82 M | -13.5 M | -13.5 M | -13.5 M | -13.5 M | -7.56 M | 9.96 M | 9.96 M | 9.96 M | 10.6 M | 10.6 M | 10.6 M | 10.6 M | 16.8 M | 16.8 M | 16.8 M | 16.8 M | 17.1 M | 17.1 M | 17.1 M | 17.1 M | 18.8 M | 18.8 M | 18.8 M | 18.8 M | 26.6 M | 26.6 M | 26.6 M | 26.6 M | 12.6 M | 12.6 M | 12.6 M | 12.6 M | 9.53 M | 9.53 M | 9.53 M | 9.53 M | 10.7 M | 10.7 M | 10.7 M | 10.7 M |
Total Shareholders Equity |
40.6 M | 49.9 M | 50.3 M | 37.7 M | 41.2 M | 46.2 M | 11.9 M | 14.6 M | 17.3 M | 22.2 M | 20.6 M | 22.6 M | 9.82 M | -13.5 M | -13.5 M | -13.5 M | -13.5 M | -7.56 M | 9.96 M | 9.96 M | 9.96 M | -1.7 M | 10.6 M | 10.6 M | 10.6 M | 16.8 M | 16.8 M | 16.8 M | 16.8 M | 17.1 M | 17.1 M | 17.1 M | 17.1 M | 18.8 M | 18.8 M | 18.8 M | 18.8 M | 26.6 M | 26.6 M | 26.6 M | 26.6 M | 12.6 M | 12.6 M | 12.6 M | 12.6 M | 9.53 M | 9.53 M | 9.53 M | 9.53 M | 10.7 M | 10.7 M | 10.7 M | 10.7 M |
All numbers in USD currency